Prosecution Insights
Last updated: November 22, 2026
Application No. 18/737,782

Anti-Trkb Monoclonal Antibodies And Methods Of Use

Non-Final OA §112
Filed
Jun 07, 2024
Priority
Nov 30, 2017 — provisional 62/592,657 +2 more
Examiner
LI, RUIXIANG
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regeneron Pharmaceuticals Inc.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
4m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
615 granted / 1034 resolved
-0.5% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
50 currently pending
Career history
1075
Total Applications
across all art units

Statute-Specific Performance

§101
6.5%
-33.5% vs TC avg
§103
19.4%
-20.6% vs TC avg
§102
17.4%
-22.6% vs TC avg
§112
46.0%
+6.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1034 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Restriction/Election 1. Claims 1, 3-4, 6-19, and 33-34 are pending and currently under consideration. Information Disclosure Statement 2. The information disclosure statement filed on 07/15/2026, 03/24/2026, 09/22/2025, 04/23/2025, 03/26/2025, and 12/12/2024 has been considered by the Examiner and an initialed copy of the form PTO-1449 is attached to the office action. Drawings 3. The drawings filed on 06/07/2024 are accepted by the Examiner. Claim Rejections[Symbol font/0xBE]35 USC § 112 (b) 4. The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 1, 3-4, 6-19, and 33-34 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. (i). Claim 1 recites “three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within an HCVR” and “three light chain CDRs (HCDR1, HCDR2, and HCDR3) contained within an LCVR”. However, the claims do not set forth distinctly the amino acid sequences of the CDRs. (ii). Claims 6-10 recite “less than about” or “greater than about”. It is unclear what the metes and bounds of the limitation are. Claims 3-4, 11-19, and 33-34 are rejected as dependent claims from claim 1. Claim Rejections [Symbol font/0xBE]35 USC § 112 (d) 6. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. 7. Claims 11-18 are rejected under 35 U.S.C. 112 (d), as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Specifically, claim 11 recites “which when injected into the hippocampus of humanized TrkB mice, demonstrates TrkB activation, as shown by an increase in TrkB phosphorylation”. However, such a recitation does not further limit the antibody or antigen-binding fragment thereof of claim 1 since the property recited in claim 11 is inherent to the structure of antibody recited in claim 1. Likewise, claims 12 -18 do not further limit the antibody or antigen-binding fragment thereof of claim 1. Conclusions 8. No claims are allowed. Advisory Information Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Vanessa Ford, can be reached on (571) 272-0857. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197. /RUIXIANG LI/Primary Examiner, Art Unit 1674 October 18, 2026
Read full office action

Prosecution Timeline

Jun 07, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799197
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
3y 1m to grant Granted Nov 17, 2026
Patent 12780917
ANTI-CADM1 ANTIBODY
2y 12m to grant Granted Nov 03, 2026
Patent 12782343
NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS
3y 3m to grant Granted Nov 03, 2026
Patent 12774315
T-Cell Receptors and Uses Thereof
5y 6m to grant Granted Oct 27, 2026
Patent 12760096
ANTIBODIES RECOGNIZING SORTILIN
3y 9m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
78%
With Interview (+18.8%)
2y 9m (~4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1034 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month